Company is advancing RE104, its proprietary, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy to provide lasting benefits to patients with underserved mental health disorders Financing will support the "RECONNECT" Phase 2 clinical trial for RE104 in postpartum depression (PPD) and expansion into other psychiatric indications of high unmet need, including adjustment disorder in cancer (ADC) MORRISTOWN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced the close of a $103 million Series A financing co-led by MPM BioImpact and Novo Holdings, with participation from Arkin Bio Capital, Mitsui & Co. Global Investment, Plaisance Capital, FemHealth Ventures, and Palo Santo. "This financing is a significant milestone for Reunion Neuroscience, and we are grateful to have the backing of MPM BioImpact and Novo Holdings, as well as a syndicate composed of top-tier institutional healthcare investors," said Greg Mayes, President and Chief Executive Officer of Reunion. "Their collective support reflects Reunion's potential to meaningfully transform mental health treatment for the large population of patients underserved by the treatment paradigm available under the current standard of care. We are committed to unlocking the full potential of RE104 to improve the lives of patients and families in our mission to address the worldwide mental health crisis." "Reunion is leading the charge to dramatically shift the way severe mental health disorders are treated," said Dr. Ansbert Gadicke, M.D., Managing Partner of MPM BioImpact. "We are proud to back Reunion's world-class team of experienced neuroscience drug developers and support the clinical advancement of RE104, which has ...